Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival

Neuroendocrinology

Volumn 104, Issue 1, 2016, Pages 26-32

  Rinke, Anja ^a   Wittenberg, Michael ^a   Schade Brittinger, Carmen ^a   Aminossadati, Behnaz ^a   Ronicke, Erdmuthe ^a   Gress, Thomas M ^a   Müller, Hans Helge ^b   Arnold, Rudolf ^b   Mossner J ^c   Novotny, A ^d   Monig H ^e   Haag, G M ^f   Pace, A ^g   Fischer, R ^h   Blitzer, M ⁱ   Wiedenmann, B ^j   Weber, M M ^k   Koop, I ^l  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k JOHANNES GUTENBERG UNIVERSITY   (Germany)

^l Ev Amalie Sieveking Krankenhaus gGmbH   (Germany)

more..

Author keywords

Midgut; Neuroendocrine tumors; Octreotide LAR; Overall survival; Somatostatin analogs

Indexed keywords

OCTREOTIDE; PLACEBO; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIGESTIVE SYSTEM TUMOR; DOUBLE BLIND PROCEDURE; HUMAN; LIVER TUMOR; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; METASTASIS; MIDGUT; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME; DISEASE FREE SURVIVAL; FEMALE; LONGITUDINAL STUDY; MALE; MORTALITY; NEUROENDOCRINE TUMORS; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; STOMACH TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROENDOCRINE TUMORS; OCTREOTIDE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84953775976     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000443612     Document Type: Article

References (12)

1. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663.
2. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlácková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
4. Arnold R, Rinke A, Klose K, Müller H, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, Arnold C: Octreotide versus octreotide plus interferon-Alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3: 761-771.
5. Arnold R, Wilke A, Rinke A, Mayer C, Kann P, Klose K, Scherag A, Hahmann M, Müller H, Barth P: Plasma chromogranin a as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6: 820-827.
6. Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, Willich SN, Wiedenmann B: Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15: 1083-1097.
7. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J, Schlumberger M, Ducreux M, Baudin E: Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 2009; 16: 585-597.
8. Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A: Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med 2014; 55: 183-190.
9. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, Koch M, Röcken C, Rindi G, Ruszniewski P, Wiedenmann B, Pape UF: Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117: 3332-3341.
10. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): results from the national cancer registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794-1803.
11. Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK: Prognostic validity of the American joint committee on cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2013; 31: 420-425.
12. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK: Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16: 885-894.